Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$94.13
+1.2%
$96.58
$79.52
$124.00
$23.52B1.36996,165 shs1.04 million shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$221.38
+0.0%
$220.96
$18.51
$221.42
$6.96B1.52928,762 shs2.69 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$54.35
+12.0%
$51.70
$22.28
$59.55
$19.26B1.056.13 million shs20.80 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$28.56
+1.0%
$28.34
$10.58
$30.33
$20.24B1.144.80 million shs5.60 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%-10.08%+1.02%-12.76%+0.24%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%0.00%0.00%0.00%+1,066.02%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+5.66%-6.83%+18.36%+101.75%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%-0.88%+0.39%+9.36%+153.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$94.13
+1.2%
$96.58
$79.52
$124.00
$23.52B1.36996,165 shs1.04 million shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$221.38
+0.0%
$220.96
$18.51
$221.42
$6.96B1.52928,762 shs2.69 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$54.35
+12.0%
$51.70
$22.28
$59.55
$19.26B1.056.13 million shs20.80 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$28.56
+1.0%
$28.34
$10.58
$30.33
$20.24B1.144.80 million shs5.60 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%-10.08%+1.02%-12.76%+0.24%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%0.00%0.00%0.00%+1,066.02%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+5.66%-6.83%+18.36%+101.75%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%-0.88%+0.39%+9.36%+153.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.72
Moderate Buy$131.6039.81% Upside
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
2.36
Hold$169.88-23.27% Downside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-34.25% Downside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$30.556.97% Upside

Current Analyst Ratings Breakdown

Latest CDTX, BNTX, ROIV, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$171.00 ➝ $158.00
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetOverweight$150.00 ➝ $140.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
4/27/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Reiterated RatingBuy$130.00
4/16/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetOverweight$22.00 ➝ $40.00
4/13/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Reiterated RatingBuy
4/10/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Boost Price TargetOverweight$125.00 ➝ $126.00
4/8/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Reiterated RatingSell (D-)
(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.33$1.35 per share69.67$86.54 per share1.09
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/A$14.92 per shareN/A
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B11.09N/AN/A$18.67 per share2.91
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M703.63N/AN/A$7.45 per share3.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%N/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$11.78N/AN/AN/AN/A-45.52%-38.31%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$1.17N/AN/AN/A-6,079.94%-19.04%-18.15%5/28/2026 (Estimated)

Latest CDTX, BNTX, ROIV, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/28/2026Q4 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.26N/AN/AN/A$3.41 millionN/A
5/5/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.59 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
2/14/2026Q4 2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/A-$0.3870N/A-$1.47N/A$1.06 billion
2/13/2026Q4 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.79-$2.11+$0.68-$2.11$611.14 million$678.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
7.49
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
4.62
4.62
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
30.66
30.66

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.89%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9031.44 million30.22 millionNo Data
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860715.70 million638.41 millionOptionable

Recent News About These Companies

Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioNTech stock logo

BioNTech NASDAQ:BNTX

$94.13 +1.11 (+1.19%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$94.97 +0.84 (+0.89%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$54.35 +5.81 (+11.97%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$56.35 +2.00 (+3.68%)
As of 05/8/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$28.56 +0.28 (+0.99%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$28.63 +0.07 (+0.25%)
As of 05/8/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.